A method for treating or preventing a disorder or a condition by double
inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a
subject in need thereof, while limiting the risks of cardiovascular
disturbances and/or organ and/or tissue toxicity, comprising the step of
administering to said subject a mixture of enantiomers of milnacipran
enriched in the (1S,2R) enantiomer of milnacipran and/or of at least one
of its metabolites, as well as their pharmaceutically-acceptable salts.